现在的位置: 首页时讯速递, 进展交流>正文
[JAMA Cardiol发表论文]:ST段抬高心梗患者院前冲击剂量糖皮质激素
2024年10月28日 时讯速递, 进展交流 [JAMA Cardiol发表论文]:ST段抬高心梗患者院前冲击剂量糖皮质激素已关闭评论

Original Investigation 

August 30, 2024

Prehospital Pulse-Dose Glucocorticoid in ST-Segment Elevation Myocardial Infarction: The PULSE-MI Randomized Clinical Trial

Jasmine Melissa Madsen, Thomas Engstrøm, Laust Emil Roelsgaard Obling, et al

JAMA Cardiol. Published online August 30, 2024. doi:10.1001/jamacardio.2024.2298

Key Points

Question  In patients with ST-segment elevation myocardial infarction (STEMI), does prehospital pulse-dose glucocorticoid treatment have a cardioprotective effect?

Findings  In this blinded, placebo-controlled, randomized clinical trial that included 530 patients with STEMI, final infarct size at 3 months was 5% in the glucocorticoid group and 6% in the placebo group, a nonsignificant difference.

Meaning  Prehospital pulse-dose glucocorticoid did not reduce final infarct size in patients with STEMI.

Abstract

Importance  In patients with ST-segment elevation myocardial infarction (STEMI), acute inflammation is related to the extent of myocardial damage and may increase infarct size. Thus, administration of pulse-dose glucocorticoid in the very early phase of infarction may reduce infarct size.

Objective  To determine the cardioprotective effect of prehospital pulse-dose glucocorticoid in patients with STEMI.

Design, Setting, and Participants  This was a 1:1 investigator-initiated, blinded, placebo-controlled, randomized clinical trial conducted between November 14, 2022, and October 17, 2023, with last follow-up on January 17, 2024. Patients 18 years and older with less than 12 hours of acute chest pain and STEMI were included in the prehospital setting throughout the Region Zealand and Capital Region of Denmark and transferred to Rigshospitalet, Denmark.

Intervention  Patients were randomly allocated to intravenous glucocorticoid (methylprednisolone, 250 mg) or placebo in the prehospital setting.

Main Outcomes and Measures  The primary outcome was final infarct size on cardiac magnetic resonance (CMR) at 3 months. The power calculation was based on an anticipated final infarct size of 13%. Secondary outcomes included CMR outcomes on acute scan and at 3 months, peak of cardiac biomarkers, clinical end points at 3 months, and adverse events.

Results  Of 530 included patients (median [IQR] age, 65 [56-75] years; 418 male [78.9%]) with STEMI, 401 (76%) were assessed for the primary outcome, with 198 patients treated with glucocorticoid and 203 with placebo. Median final infarct size was similar in the treatment groups (glucocorticoid, 5%; IQR, 2%-11% vs placebo, 6%; IQR, 2%-13%; P = .24). Compared with placebo, the glucocorticoid group had smaller acute infarct size (odds ratio, 0.78; 95% CI, 0.61-1.00), less microvascular obstruction (relative risk ratio, 0.83; 95% CI, 0.71-0.99), and greater acute left ventricular ejection fraction (mean difference, 4.44%; 95% CI, 2.01%-6.87%). Other secondary outcomes were similar in both groups.

Conclusions and Relevance  In patients with STEMI, treatment with prehospital pulse-dose glucocorticoid did not reduce final infarct size after 3 months. However, the trial was likely underpowered as the final infarct size was smaller than anticipated. The glucocorticoid group had improved acute parameters compared with placebo.

Trial Registration  ClinicalTrials.gov Identifier: NCT05462730

抱歉!评论已关闭.

×
腾讯微博